Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -19.72%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
Biodesix, Inc. demonstrated strong revenue growth and promising advancements in their lung diagnostic and development services. However, the company continues to face financial challenges with a significant net loss and increased operating expenses. The successful pilot and sales expansion plans highlight a strategic focus towards growth, yet cash burn remains a concern.Company Guidance
During the Biodesix, Inc. Q4 2024 earnings call, CEO Scott Hutton highlighted the company's strong financial performance and strategic plans. The company reported $71.3 million in total revenue for the year, marking a 45% increase compared to 2023, and an improvement in gross margins to 78%. Lung diagnostic testing revenues grew by 43% with a 40% increase in test volumes. Biodesix plans to expand its sales force, adding six sales teammates per quarter in 2025, aiming for a total of 95 teammates by year-end to support 50 territories. The company expects total revenue for 2025 to be between $92 and $95 million, maintaining gross margins in the mid to upper seventies, and achieving adjusted EBITDA profitability in the second half of the year. Biodesix also discussed their ongoing clinical studies, including the Clarify and Altitude studies, which aim to further validate their diagnostic tests and potentially influence clinical guidelines.Significant Revenue Growth
Biodesix, Inc. reported a total revenue of $71.3 million for 2024, representing a 45% increase over 2023 and exceeding the midpoint of their improved revenue guidance.
Strong Performance in Lung Diagnostic Testing
Lung diagnostic testing revenue grew by 43% over 2023, driven by a 40% increase in test volume and expanded reimbursement coverage.
Diagnostic Development Services Surge
There was a 70% increase in diagnostic development services revenue year-over-year, with $12.2 million under contract but not yet recognized as revenue, up 54% from 2023.
Gross Margin Improvement
Gross margins increased to 78% for the year, which is a five percentage point increase over the full year of 2023.
Path to Profitability
Biodesix, Inc. improved their adjusted EBITDA loss by 32% and aims to achieve adjusted EBITDA profitability in the second half of 2025.
Successful Pilot Program and Sales Expansion
A pilot program to expand the sales force and focus on primary care referral networks was successful, leading to a plan to add approximately six sales teammates per quarter in 2025.
---
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BDSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $0.71 | $0.72 | +1.41% |
| Nov 01, 2024 | $1.70 | $1.30 | -23.53% |
| Aug 07, 2024 | $1.59 | $1.64 | +3.14% |
| May 08, 2024 | $1.55 | $1.55 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biodesix (BDSX) report earnings?
Biodesix (BDSX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Biodesix (BDSX) earnings time?
Biodesix (BDSX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BDSX EPS forecast?
BDSX EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---